July 7, 2022 -- The U.S. Food and Drug Administration (FDA) approved a content uniformity (CU) method from Teva Pharmaceuticals that uses the Agilent TRS100 Raman quantitative pharmaceutical analysis system.
As an Agilent Raman spectroscopy customer, Teva Pharmaceuticals developed a method of CU that determines how much active pharmaceutical ingredient (API) is inside a tablet or capsule and whether the API is uniform across a batch. The method is a fast, whole-sample analysis that negates the sample preparation stages and allows the test to be completed in a matter of minutes, Teva Pharmaceuticals said.
Copyright © 2022 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
